Open AccessTracking Down Response and Resistance to TRK Inhibitors
Author(s) -
Ross A. Okimoto,
Trever G. Bivona
Publication year - 2016
Publication title -
cancer discovery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.795
H-Index - 163
eISSN - 2159-8290
pISSN - 2159-8274
DOI - 10.1158/2159-8290.cd-15-1352
Subject(s) - trk receptor , lmna , biomarker , cancer , cancer research , computational biology , clinical trial , medicine , bioinformatics , biology , genetics , mutation , gene , receptor , neurotrophin
Two recent studies validate the LMNA-NTRK1 fusion as an oncogenic driver and therapeutic target of TRK inhibitors. The LMNA-NTRK1 fusion occurs at low frequency across multiple tumor types. The studies highlight the increasing need to develop molecular biomarker-based clinical trials across cancer subtypes.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom